Cardiol Therapeutics Inc.

REMINDER: Cardiol Therapeutics management will participate in a Fireside Chat at the B. Riley Securities Mind, Muscle & Vision Summit tomorrow at 12:20 p.m. EDT. 📅 Thursday, July 16 at 12:20 p.m. EDT 📍 InterContinental Boston Hotel, in Abigail Adams Salon B #Biotech #LifeSciences #Event $CRDL

The full publication is available in the Journal of the American Heart Association: ahajournals.org/doi/full/10.11…

We've announced the publication of our Phase II MAvERIC study results in the Journal of the American Heart Association. Peer-reviewed JAHA publication strengthens the foundation for Cardiol’s pivotal Phase III MAVERIC trial as enrollment nears completion. $CRDL cardiolrx.com/cardiol-therap…

We're pleased to share that Cardiol Therapeutics will participate in a Fireside Chat at the B. Riley Securities Mind, Muscle & Vision Summit in Boston, MA, on July 16, 2026, at 12:20 p.m. EDT. 📅 Thursday, July 16 at 12:20 p.m. EDT 📍 InterContinental Boston Hotel, in Abigail Adams Salon B #Biotech #LifeSciences #HeartHealth $CRDL cardiolrx.com/cardiol-therap…

Please note that any opinion, estimates or forecasts regarding Cardiol’s performance made by the analysts are theirs alone and do not represent opinions, estimates or forecasts by Cardiol or its management. Cardiol does not by its reference or distribution imply its endorsement of or concurrence with such statements.

On June 30th, @CG_Driven hosted a virtual KOL Event presented by Edward Nash, featuring @CardiolRx MAVERIC trial SC member and Principal Investigator, Paul Cremer, MD, associate professor in the departments of medicine and radiology at Northwestern University. 📺 Watch the replay of the KOL event – register here: webcaster5.com/Webcast/Page/2…

Happy Canada Day from all of us at Cardiol Therapeutics. Today, we join Canadians across the country in celebrating the people, communities, and spirit that make Canada home. #CanadaDay

Congratulations to Dr. Joseph A. Hill, our Scientific Advisory Board member, on 10 incredible years leading @CircAHA as Editor-in-Chief! Under his watch, the journal's impact factor doubled from 19 → 41, making it the #1 cardiovascular journal globally. Now a 2026 @American_Heart Gold Heart Award honoree — well deserved! #HeartHealth #CardioTwitter $CRDL heart.org/en/around-the-…

Why is heart failure on the rise? David Elsley discusses how diabetes, obesity, and high blood pressure are contributing to a growing global burden, underscoring the need for improved treatment options. $CRDL

We've announced the results from our 2026 Annual General Meeting of Shareholders held virtually on June 24, 2026. A webcast of the AGM will be accessible under “Events & Presentations” in the Investors section of the Cardiol website. $CRDL cardiolrx.com/cardiol-therap…

Reminder: Cardiol Therapeutics’ virtual Annual General Meeting of Shareholders begins in 30 minutes. The AGM will be webcast today at 4:30 p.m. EDT. Join here: meetings.400.lumiconnect.com/r/participant/… $CRDL

Access the live webcast: meetings.lumiconnect.com/400-405-294-535 Additional details, including how to participate and vote, are available at: cardiolrx.com/investors/even…

Today we announced that our 2026 Annual General Meeting of Shareholders will be held virtually on June 24, 2026 at 4:30 p.m. EDT. $CRDL cardiolrx.com/cardiol-therap…

We're building toward multiple high-impact milestones — all tied to one mission: treating inflammation in heart disease. Pivotal Phase III MAVERIC topline data. CRD-38 IND submission. Rare disease expansion. Strategic partnerships. The key catalysts are lined up. $CRDL #Cardiol #Biotech #HeartDisease #Inflammation

Inflammation doesn't stop when symptoms do — and the structural consequences show up in the data. In our ARCHER trial, CardiolRx™ reduced left ventricular (LV) mass by 9.2 grams in patients with acute myocarditis — comparable to reductions seen with widely prescribed therapies for heart failure, diabetes, and obesity.. First evidence of structural cardiac recovery. In just 12 weeks. $CRDL 🔗 cardiolrx.com #Cardiol #Myocarditis #HeartDisease #Biotech #Inflammation #CRDL

A person with recurrent pericarditis knows the feeling. The pain subsides. Life starts to normalize. And then, weeks or months later, it comes back. That cycle of recurrence is one of the most difficult aspects of the disease. Treatments that provide short-term relief matter. But therapies that can prevent the next episode from happening are what patients and their physicians are looking for. That is why MAVERIC’s primary endpoint is freedom from a new episode of recurrent pericarditis after six months of treatment. Not symptom management. Recurrence prevention. $CRDL

From approximately six episodes per year to less than one. CEO David Elsley discusses the Phase II MAvERIC findings in recurrent pericarditis, and how those data helped form the basis for the now-enrolling pivotal Phase III MAVERIC trial. $CRDL

Cardiol's President/CEO David Elsley sat down with Stocks to Watch to discuss our approach to targeting inflammation in heart disease — and what's ahead for $CRDL. 🎥 Watch the full interview: youtube.com/watch?v=NXkzgf… #HeartDisease #Biotech #CRDL #Pericarditis #Inflammation

REPLAY: President/CEO David Elsley & CMO/Head of R&D Andrew Hamer joined @HCWCO yesterday in a Fireside Chat hosted by Brandon Folkes to discuss the pivotal Phase III MAVERIC trial, key value-driving milestones, and development of CRD-38. 🔗 Watch here: journey.ct.events/view/8d043006-…

REMINDER: Cardiol Therapeutics will be presenting a Fireside Chat today at 1:30 p.m. ET at the H.C. Wainwright 4th Annual BioConnect Investor Conference at the Nasdaq in New York City. $CRDL 📺Watch our Fireside Chat live via webcast — register here: journey.ct.events/view/8d043006-…